scholarly journals Bovine Herpes Virus Expressing Envelope Protein(E2) of Bovine Viral Diarrhea Virus As a Vaccine Candidate.

1999 ◽  
Vol 61 (4) ◽  
pp. 395-401 ◽  
Author(s):  
Chang-Hee Kweon ◽  
Seung-Won Kang ◽  
Eun-Jin Choi ◽  
Yung-Bai Kang
Keyword(s):  
Bovine Viral Diarrhea Virus ◽  
Envelope Protein ◽  
Herpes Virus ◽  
Vaccine Candidate ◽  
Bovine Viral Diarrhea ◽  
Diarrhea Virus ◽  
Viral Diarrhea ◽  
Herpès Virus ◽  
Viral Diarrhea Virus

scholarly journals A β-Hairpin Motif in the Envelope Protein E2 Mediates Receptor Binding of Bovine Viral Diarrhea Virus

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1157
Author(s):  
Fernando Merwaiss ◽  
María José Pascual ◽  
María Trinidad Pomilio ◽  
María Gabriela Lopez ◽  
Oscar A. Taboga ◽  
...  
Keyword(s):  
Bovine Viral Diarrhea Virus ◽  
Envelope Protein ◽  
Viral Population ◽  
Cell Culture Supernatant ◽  
Receptor Interaction ◽  
Bovine Viral Diarrhea ◽  
Wild Type ◽  
Diarrhea Virus ◽  
Viral Diarrhea ◽  
Viral Diarrhea Virus

Pestivirus envelope protein E2 is crucial to virus infection and accomplishes virus-receptor interaction during entry. However, mapping of E2 residues mediating these interactions has remained unexplored. In this study, to investigate the structure-function relationship for a β-hairpin motif exposed to the solvent in the crystal structure of bovine viral diarrhea virus (BVDV) E2, we designed two amino acidic substitutions that result in a change of electrostatic potential. First, using wild type and mutant E2 expressed as soluble recombinant proteins, we found that the mutant protein had reduced binding to susceptible cells compared to wild type and diminished ability to inhibit BVDV infection, suggesting a lower affinity for BVDV receptors. We then analyzed the effect of β-hairpin mutations in the context of recombinant viral particles. Mutant viruses recovered from cell culture supernatant after transfection of recombinant RNA had almost completely inhibited ability to re-infect susceptible cells, indicating an impact of mutations on BVDV infectivity. Finally, sequential passaging of the mutant virus resulted in the selection of a viral population in which β-hairpin mutations reverted to the wild type sequence to restore infectivity. Taken together, our results show that this conserved region of the E2 protein is critical for the interaction with host cell receptors.

scholarly journals Bungowannah Pestivirus Chimeras as Novel Double Marker Vaccine Strategy against Bovine Viral Diarrhea Virus

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 88
Author(s):  
Susanne Koethe ◽  
Patricia König ◽  
Kerstin Wernike ◽  
Jana Schulz ◽  
Ilona Reimann ◽  
...  
Keyword(s):  
Bovine Viral Diarrhea Virus ◽  
Vaccine Candidate ◽  
Economic Losses ◽  
Major Type ◽  
Bovine Viral Diarrhea ◽  
Type I ◽  
Diarrhea Virus ◽  
Marker Vaccine ◽  
Viral Diarrhea ◽  
Viral Diarrhea Virus

Marker or DIVA (differentiation of infected from vaccinated animals) vaccines are beneficial tools for the eradication of animal diseases in regions with a high prevalence of the designated disease. Bovine viral diarrhea virus (BVDV)-1 (syn. Pestivirus A) is a flavivirus that infects predominantly cattle resulting in major economic losses. An increasing number of countries have implemented BVDV eradication programs that focus on the detection and removal of persistently infected cattle. No efficient marker or DIVA vaccine is yet commercially available to drive the eradication success, to prevent fetal infection and to allow serological monitoring of the BVDV status in vaccinated farms. Bungowannah virus (BuPV, species Pestivirus F), a related member of the genus Pestivirus with a restricted prevalence to a single pig farm complex in Australia, was chosen as the genetic backbone for a marker vaccine candidate. The glycoproteins E1 and E2 of BuPV were substituted by the heterologous E1 and E2, which are major immunogens, of the BVDV-1 strain CP7. In addition, the candidate vaccine was further attenuated by the introduction of a deletion within the Npro protein coding sequence, a major type I interferon inhibitor. Immunization of cattle with the chimeric vaccine virus BuPV_ΔNpro_E1E2 CP7 (modified live or inactivated) followed by a subsequent experimental challenge infection confirmed the safety of the prototype strain and provided a high level of clinical protection against BVDV-1. The serological discrimination of vaccinated cattle could be enabled by the combined detection of BVDV-1 E2- in the absence of both BVDV NS3- and BVDV Erns-specific antibodies. The study demonstrates for the first time the generation and application of an efficient BVDV-1 modified double marker vaccine candidate that is based on the genetic background of BuPV accompanied by commercially available serological marker ELISA systems.

Sign in / Sign up

Export Citation Format

Share Document